Pullan's Pieces #133                                     
Pullan's Pieces #133
January 2018
BD News and Analysis for  Biotech and Pharma
Dear --FNAME--,
2017 has been a good year with 6 deals signed and 2 in process (keeping my fingers crossed).  Thanks to all our clients and to all with whom we interacted in our partnering processes!  

We are about to begin the New Year with the annual craziness of JPM in San Francisco.  I love seeing folks while running from meeting to meeting.  

And at the end of this month, I will be moderating a panel on bispecifics.  With a great panel, this should be a fun webinar, talking about the potential, the challenges of multi-targeting in 1 molecule. 

May 2018 be a great year for you! 


1.  Bispecifics - deals up and away

2.   Infographic:  Licensing deals in 2017

3.  Infographic:  M&A deals in 2017

4.  Trevor:   What's out there, licensing opportunities at Biotech Showcase 

Do sign up for the bispecifics webinar.  If you can't make it live, you can still get the recording and later the whitepaper.  



Bispecifics:  Ready for our webinar?

Deals for bispecifics increase year by year. 

And the total value of deals involving bispecifics is going up yearly too.  

Tune in January 30th for a ShareVault webinar on bispecifics and related technology, with input from business development, commercial and science! We will talk about when 2 is better than 1 as well as the challenges.  
Infographic:  Licensing deals in 2017
Infographic:  2017 M&A deals

Trevor:  What's out there? Licensing at Biotech Showcase

With another JPM upon us, we thought it would be interesting to take a snapshot of what’s happening out there by taking a broad look at assets available for in-licensing at the Biotech Showcase.

Overall, there are 881 different biotech/pharma products available for in-licensing this year. 

  • Oncology assets dwarf the other therapeutic areas
  • CNS and infectious disease assets in 2nd and 3rd place, respectively. 
  • Several other therapeutic areas are all represented with between 20-50 opportunities each.  

Therapeutic Products Available for In-Licensing at Biotech Showcase by Therapeutic Area

By modality, small molecules are the most highly represented molecule type with over half of all opportunities with antibody-based therapies accounting for roughly 20% of available assets. 


And a closer look by therapeutic area shows the way that the primary molecule types play out within therapeutic areas.  Antibody-based therapeutics are more common in oncology and ophthalmology than they are in the other therapeutic areas.

Primary Modality Comparison within Therapeutic Area

We look forward to seeing you in San Francisco.  It is a great way to start the New Year!
9360 W. Flamingo Road, Suite 110-554 Las Vegas, NV 89147